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Each of the two stem-loop structures in the HIV-2 TAR (TAR-2) RNA element contains a dinucleotide bulge that specifies 
a binding site in vitro for the HIV-2 Tat transactivator protein. A TAR-2 RNA with both bulges deleted is very weakly 
transact/rated in vivo by the HIV-2 Tat protein. To gain insight into general features of Tat protein:TAR RNA interactions, 
we have analyzed the significance of the dinucleotide bulges in TAR-2 RNA for in vitro binding and in vivo transact/vat/on 
by the related HIV-1 Tat protein. The HIV-1 Tat protein has been shown previously to bind efficiently to wild-type TAR-2 
RNA and fully transactivates the HIV-2 LTR. We found that the 5' proximal bulge and the 3' distal bulge appear to specify 
a high and low affinity binding site in vitro, respectively, for the HIV-1 Tat protein. Wild-type TAR-2 RNA was found to be 
able to bind HIV-1 Tat proteins simultaneously at each bulge binding site in Vitro. A TAR-2 RNA with both bulges deleted 
was greatly defective for in vitro binding by the HIV-1 Tat protein. Surprisingly, the TAR-2 RNA with both bulges deleted 
was efficiently transact/rated in vivo by the HIV-1 Tat protein, indicating that the HIV-1 Tat protein (but not HIV-2 Tat protein) 
is able to strongly activate transcription of a TAR RNA with no apparent bulge binding site. © 1995 Academic Press, Inc. 
The pathogenic retroviruses human immunodeficiency 
virus types 1 and 2 (HIV-1 and HIV-2) encode closely 
related Tat proteins that are necessary for high levels of 
transcription directed by the viral long terminal repeat 
(LTR) sequences (1). Tat proteins function through a di- 
rect interaction with the TAR RNA element that is con- 
tained in the 5' ends of viral transcripts. By binding to 
TAR RNA in nascent transcripts, Tat proteins are able to 
stimulate transcriptional initiation and elongation through 
a mechanism that remains to be elucidated (2). Both HIV- 
1 and HIVe2 Tat proteins contain a stretch of basic amino 
acid residues that comprises the TAR RNA binding do- 
main. The RNA binding domain of HIV-1 Tat has high 
affinity for TAR RNAs of both HIV-1 and HIV-2; conse- 
quently, the HIV-1 Tat protein has full transactivation 
function for both the HIV-1 and HIV-2 LTRs (3-7). In con- 
trast, the RNA binding domain of HIV-2 Tat has high 
affinity only for its cognate HIV-2 TAR RNA; consequently, 
the HIV-2 Tat protein has full transact/vat/on function for 
the HIV-2 LTR and relatively weak function for the HIV-1 
LTR (8, 9). 
Recognition of TAR RNA by Tat proteins has been stud- 
ied extensively in the HIV-1 system (10). HIV-1 TAR RNA 
(TAR-l) encompasses nucleotides +1 to +44 relative to 
the site of transcription initiation. TAR-1 RNA forms a 
single stem-loop structure, with nucleotides +30 to +35 
forming the loop at the apex of the double-strand stem 
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and nucleotides +23 to +25 forming a trinucleotide 
bulge in the stem. The U23 nucleotide and a few base 
pairs surrounding the TAR-1 bulge are recognized and 
bound directly by basic amino acid residues in the HIV- 
1 Tat RNA binding domain (11-14). Amino acid residues 
flanking the HIV-1 Tat RNA binding domain are also in- 
volved in binding to TAR-1 RNA (15, 16). Additionally, 
genetic experiments indicate that a cellular factor inter- 
acts with the TAR-1 loop to facilitate HIV-1 Tat binding 
in vivo (17-20). 
HIV-2 TAR RNA (]-AR-2) encompasses nucleotides +1 
to +99 that form two stem-loop structures similar to the 
single TAR-1 stem-loop (3, 5, 21, 22). Deletion analyses 
have shown that each TAR-2 stem-loop can function 
independently, although the 5' proximal structure is sig- 
nificantly more active than the 3 r distal structure (5, 6). 
By analogy to TAR-l, the conserved loop sequences at 
the apex of both stem-loops in TAR-2 are likely to inter- 
act with a cellular factor to facilitate HIV-2 Tat binding 
in vivo (5). Each of the TAR-2 stem-loops contains a 
dinucleotide bulge similar in position to the crucial tri- 
nucleotide bulge in TAR-1 RNA. Our analysis of these 
bulges indicated that each bulge appears to specify a 
distinct binding site in vitro for the HIV-2 Tat protein (22). 
We showed that deletion of both bulges reduced HIV-2 
Tat transact/vat/on of the TAR-2 element in vivo to a level 
less than 5% that of wild-type TAR-2. Deletion of the 5' 
proximal bulge reduced HIV-2 Tat transact/vat/on in v/vo 
to a level approximately 30% that of wild-type TAR-2. 
Deletion of the 3' distal bulge had no measurable effect 
673 0042-6822/95 $6.00 Copyright © 1995 by Academic Press. rno. 
All riglqts of reproduction i any form reserved. 
674 SHORT COMMUNICATIONS 
in vivo, suggesting that in the wild-type TAR-2 element 
the 3' bulge binding site does not contribute to HIV-2 Tat 
transactivation in vivo. 
To gain further insight into general principles involved 
in recognition of TAR RNA by Tat proteins, we examined 
in this study the functional significance of the dinucleo- 
tide bulges in TAR-2 RNA on in vitro binding and in vivo 
transactivation by the HIV-1 Tat protein. Plasmid con- 
structs used in this study have been described in detail 
previously (22). Plasmids used to produce Wtx, A,UA, 
UU:A, and A:A TAR-2 RNAs by in vitro.transcription 
were based upon the pGEM3Zf(+) vector (Promega). For 
construction of HIV-2 LTR-CAT reporter plasmids, Wtx, 
A:UA, UU:A, and A:A TAR-2 elements were inserted into 
the pBA-CAT plasmid (23); these HIV-2 LTRs contained 
nucleotides -252 to +123. The HIV-2 LTR-CAT plasmid 
named TAR-2(-) contains a deletion of nucleotides +13 
to +123; the HIV-2 LTR-CAT plasmid named (CTG)17 
contains an insertion at +13 in TAR-2(-) of a 131-bp 
fragment containing 17 repeats of the sequence (CTG) 
followed by the sequence GACCTGCAGGCATGCAAGC. 
For production of 32p-labeled antisense RNA probes, the 
TAR-2 elements were inserted into the pGEM4Z vector 
(Promega). To express the HIV-1 Tat protein (86 residues, 
both coding exons of isolate HXB2), the full-length cDNA 
was inserted into the pBC12/CMV vector (24) that utilizes 
the cytomegalovirus immediate-early promoter for ex- 
pression in mammalian cells. 
For production of TAR-2 RNAs for gel shift assays, 
in vitro transcription reactions were performed and full- 
length 3ZP-labeled TAR-2 RNAs were gel purified and 
processed as described (22). For purification of the HIV- 
1 Tat protein (HXB2 isolate) for gel shift assays, the 86 
residue Tat protein was expressed in Escherichia coil as 
a glutathione S-transferase (GST) fusion as described 
(25). The Tat protein was cleaved from the GST moiety 
of the fusion by digestion with thrombin; cleaved Tat 
protein was eluted from the GST-glutathione-Sepha- 
rose bead complex, stored at -80 °, and subsequently 
used in gel shift assays. 
Gel shift assays (10 #1) contained 0.4 prod1 (40 nM) of 
uniformly labeled RNA probe, 0.5 #g tRNA, 2 ng poly(I.C), 
50 mMTris-HCI (pH 7.5), 20 mM KCI, and 0-8 pmol (0- 
800 nM) of HIV-1 Tat protein. After incubation at room 
temperature for 10 min, the reaction mixtures were 
loaded on 6% nondenaturing polyacrylamide gels (acryl- 
amide:bisacrylamide of 75=1) in 50 mM Tris-glycine 
buffer (pH 8.8); gels were run at room temperature. Gels 
were dried and exposed to X-ray film with an intensifying 
screen at -80 °. Gels were quantified with a Betagen 
Betascope 603 scanner. Each experiment presented is 
representative of experiments repeated several times. 
For in vivo transactivation assays, transfections were 
carried out in HeLa cells using the calcium phosphate 
method. Culture dishes (6 cm) were transfected with 5 #g 
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FiG. 1, Secondary structure for HIV-2(RoD) TAR RNA as predicted from 
computer analysis (5) and subsequently experimentally verified (22), 
Mutant TAR-2 elements analyzed in this study are indicated. 
of HIV-2 LTR-CAT reporter plasmids plus the indicated 
amount of HIV-1 or HIV-2 Tat activator plasmids. These 
activator plasmids (22) are under control of the OMV 
immediate-early promoter and express the 86 amino acid 
residue (two exon) Tat-1 protein (isolate HXB2) and the 
99 .residue (first exon) Tat-2 protein (ROD isolate). The 
total amount of activator plasmid was adjusted to a total 
of 1000 ng by the addition of the appropriate amount of 
vector plasmid. Cell extracts were prepared at 48 hr post- 
transfection and CAT enzyme assays were performed 
under conditions where conversion of chloramphenicol 
to its acetylated forms was less than 50%. After thin-layer 
chromatography, CAT assays were quantified with a Be- 
tagen Betascope 603 scanner. CAT units were arbitrarily 
defined as described (22). Each experiment presented is 
representative of experiments repeated several times. 
For RNase protection assays, total cytoplasmic RNA was 
isolated from HeLa cells at 48 hr post-transfection bythe 
Nonidet P-40 method (26). RNA samples were digested 
with RNase-free DNase. To produce 32p-labeled anti- 
sense RNA probes, the pGEM4Z/TAR-2 plasmids were 
lin&arized with Pstl. RNase protection assays were per- 
formed as described (22). 
As shown in Fig. 1, nucleotides +1 to +123 of HIV-2 
RNA form three stem-loop structures. Stem-loop1 and 
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stem-loop2, but not stem-loop3, constitute the TAR-2 
RNA genetic element that responds to transactivation by 
both HIV-2 and HIV-1 Tat proteins (5, 6). Both stem-loop1 
and stem-loop2 contain single dinucleotide bulges that 
appear to specify two distinct binding sites for the HIV- 
2 Tat protein both in vivo and in vitro (22). For wild-type 
TAR-2 RNA in this study, we used a phenotypically wild- 
type element called Wtx TAR-2. The wt× TAR-2 element 
contains substitution of AGA for wild-type nucleotides 
GOG at 4-10 to +12; these substitutions create an Xbal 
restriction enzyme site that facilitated the insertion of 
mutant TAR-2 RNA elements into HIV-2 LTR-CAT re- 
porter plasmids. The wt× TAR-2 element is indistinguish- 
able from the natural wild-type TAR-2 element with re- 
spect to transactivation in vivo by the HIV-1 and HIV- 
2 Tat proteins (22). Additionally, the Wtx TAR-2 RNA is 
equivalent to wild-type TAR-2 RNA for in vitro binding to 
purified HIV-2 Tat protein (9, 22). To evaluate the signifi- 
cance of bulge1 and bulge2 for purified HIV-1 Tat binding 
t0 TAR-2 RNAin vitro, we used a gel shift assayto analyze 
mutant TAR-2 elements with deletion of bulge1, bulge2, 
or bulge1+2; these TAR-2 elements are called A,UA, 
UU=A, and A:A,  respectively. As shown in Fig. 2A, two 
distinct protein=RNA complexes were observed for the Tat 
protein and Wtx TAR RNA. A rapidly migrating complex was 
seen at the lowest Tat concentration (1:1 molar ratio of 
pr0tein:RNA). An additional more slowly migrating complex 
was observed for Wtx TAR-2 RNA and Tat protein concentra- 
tions ~>3,1 molar ratio. This pattern of protein=RNA com- 
plexes is similar to the pattern that we reported previously 
for HIV-1 Tat and the natural wild-type TAR-2 RNA (9). Quan- 
titation of the gel shown in Fig. 2A showed that a Tat molar 
ratio of approximately 3=1 (114 nM Tat-l) was required to 
bind 50% of the input Wtx RNA probe (Fig. 2B). 
For the A=UA and UU:A bulge deletion RNAs, only 
single protein=RNA complexes were observed. These 
complexes migrated similarly to the rapidly migrating 
complex seen with the Wtx RNA. The binding affinities of 
the A:UA and UU:A RNAs to the HIV-1 Tat protein were 
notably different. The UU:A mutant produced a pro- 
tein=RNA complex at molar ratios />1:1, while the A:UA 
mutant produced a complex only at molar ratios ~>5,1. 
For the double bulge deletion A=A RNA, no distinct pro- 
tein:RNA complex was observed at any Tat concentra- 
tion. The A=A RNA, however, displayed a smear of pro- 
tein:RNA material at molar ratios >t5:1 that migrated 
slightly more slowly than the free probe. Quantitation of 
the gel shown in Fig. 2A showed that an HIV-1 Tat molar 
ratio of approximately 5=1 (176 nM Tat-l) was required 
to shift 50% of the UU=A RNA probe, while molar ratios 
>20=1 (>800 nM Tat-l) were required to shift 50% of the 
A:UA and A :A  RNA probes (Fig. 2B). These data indicate 
that under the conditions of our gel shift assay, the appar- 
ent Kds of Tat-1 for the A=UA and A=A RNAs are at least 
eight-fold greater than that of the wt× RNA. 
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FiG. 2. Gel shift assay with TAR-2 RNAs with bulge deletions (A) The 
indicated molar ratios of HiV-1 Tat protein were incubated with the 
indicated 32P-labeled TAR-2 RNAs and analyzed on a 6% native poly- 
acrylamide gel. (B) The percentage of free (unbound) a2p-labeled TAR- 
2 RNA probe (40 nM input) in the gel at each Tat-1 concentration was 
measured with a Betagen Betascope 603 scanner. 
These in vitro binding experiments indicate that the 
wt× TAR-2 RNA contains two distinct HIV-1 Tat binding 
sites that are specified by bulge1 and bulge2. Bulge1 
appears to specify a higher affinity HIV-1 Tat binding site 
than does bulge2, as indicated by the observation that 
the UU=A RNA binds the Tat protein with significantly 
higher affinity than does the A:UA RNA. Additionally, the 
slowly migrating complex seen with wt× RNA is likely to 
be a single RNA bound by two HIV-1 Tat proteins, as 
only single gel shift complexes were seen with the UU=A 
and A,UA RNAs. 
As we reported previously, the protein:RNA complexes 
formed between TAR-2 RNA and the HIV-1 Tat protein 
migrated in gel shift assays with notably better resolution 
than complexes formed between TAR-2 RNA and its cog- 
nate HIV-2 Tat protein (9, 22). The explanation for this 
difference is unknown, but it may reflect the different 
tertiary structures of the Tat proteins. Gel filtration, glyc- 
erol gradient centrifugation, and relative sensitivity to 
proteolysis indicates that the HIV-1 Tat protein pos- 
sesses a compact and perhaps globular structure, while 
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FiG. 3. (A) HIV-1 Tat transactivation in vivo of TAR-2 bulge deletion mutants and TAR-2 deletion mutants. HIV-2 LTR-CAT reporter plasmids 
containing the Wtx, UU:A, A=UA, A:A, TAR-2 ( - )  deletion of nucleotides +13 to +123), and (CTG)~7 (insertion at+13 in TAR-2 ( - )  of a 131-bp 
fragment containing 17 repeats of the sequence (CTG)) LTRs were transfected into HeLa cells along with 0 (vector alone), 10, 100, or 1000 ng HIV- 
1 Tat expression plasmid. CAT expression was measured at 48 hr post-transfection. (B) HIW2 Tat transactivation in vivo of wt× and A:L& TAR-2 
deletion mutant. HlV-2 LTR-CAT reporter plasmids containing the Wtx or /k:A LTR were traqsfected into HeLa cells along with the HIV-2 Tat 
expression plasmid and the CAT expression was measured as described in A. 
the HIV-2 Tat protein possesses an asymmetric struc- 
ture (25). 
To assess the significance of bulge1 and bulge2 on 
HIV-1 Tat binding in vivo, HIV-2 LTR-CAT reporter plas- 
mids containing the wt×, UU:A, A:UA, and A :A  TAR-2 
elements were analyzed for activation by the HIV-1 Tat 
protein. These reporter plasmids were cotransfected into 
HeLa cells with increasing amounts of a HIV-1 Tat ex- 
pression plasmid and CAT expression was measured 
at 48 hr post-transfection (Fig. 3A). The wt× and UU:A 
reporters responded similarly to transactivation by Tat, 
expressing 1799 and 2170 CAT units, respectively, with 
1000 ng Tat plasmid. With 1000 ng Tat-1 plasmid, the 
A:UA reporter produced 638 CAT units, or 35% that of 
the wt× reporter. With 1000 ng Tat-1 plasmid, the A :A  
reporter produced 1028 CAT units, or 57% that of the wt× 
reporter. This surprising result with the A :A  reporter 
contrasts with very weak transactivation of the z&:A re- 
porter by the HIV-2 Tat protein; the z&:A reporter was 
activated by the HIV-2 Tat protein to a level only 5% that 
of the Wtx reporter (Fig. 3B., Ref. 22). In three additional 
independent experiments, the A :A  reporter showed re- 
sponses at 1000 ng Tat-1 plasmid that ranged from 42 
to 90% that of the Wtx reporter. In these additional experi- 
ments, the A,UA reporter responded more to Tat-1 than 
the level shown in Fig. 3, and in some cases the A:LIA 
reporter was as active as the Wtx reporter. 
To confirm that CAT enzyme levels reflected the rela- 
tive levels of CAT mRNA, RNase protection assays were 
performed to measure correctly initiated RNAs from vari- 
ous HIV-2 LTRs used in this study. HeLa cells were co- 
transfected with the HIV-1 Tat expression plasmid and 
the wt×, UU:A, A:UA, or A :A  reporters and total cyto- 
plasmic RNA was extracted at 48 hr post-transfection. 
Homologous S2P-labeled antisense RNA probes were 
used for the RNase protection assay (Fig. 4). Consistent 
with the CAT enzyme measurements, the RNase protec- 
tion results demonstrated that HIV-1 Tat stimulated the 
wt× and all bulge deletion HIV-2 LTR reporters to produce 
high levels of correctly initiated mRNA. 
The observation that HIV-1 Tat transactivated the A:A 
TAR-2 element in vivo to levels approximately 50% that 
of the Wtx TAR-2 element suggested that Tat may be able 
to activate the HIV-2 LTR in our experiments through a 
TAR-independent mechanism. Such a TARqndependent 
mechanism has been observed for HIV-1 Tat transactiva- 
tion of the HIV-1 LTR in phorbal myristate acetate-stimu- 
lated JurkatT cells (27) and in astrocytic gNal cells (28). To 
determine whether HIV-1 Tat was acting predominantly 
through the TAR-2 element in our experiments, an HIV- 
2 LTR CAT reporter plasmid was analyzed that lacked 
the entire TAR-2 element. This mutant, named TAR-2(-), 
contained deletion of nucleotides +13 to +123 in the 
HIV-2 LTR. An additional TAR-less reporter plasmid, 
named (CTG)~7, was analyzed that contained an insertion 
at +13 in TAR-2(-) of a 131-bp fragment containing re- 
peats of the sequence (CTG). The wt×, bulge deletions, 
and TAR-less reporter plasmids were cotransfected into 
HeLa cells with increasing amounts of the Tat expression 
plasmid and CAT expression was measured at 48 hr 
post-transfection (Fig. 3). The TAR-2(-) reporter showed 
4.6 CAT units with 1000 ng Tat plasmid, or 0.3% that of 
the Wtx reporter. The (CTG)17 reporter showed 4.4 CAT 
units with 1000 ng Tat plasmid, or 0.2% that of the wt× 
reporter. We conclude that HIV-1 Tat transactivation of 
the HIV-2 LTR in this study functions through the TAR-2 
RNA element. 
In this study, we have analyzed the functional signifi- 
cance of the dinucleotide bulges in the two stem-loop 
structures of TAR-2 RNA for binding in vitro and transacti- 
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into HeLa cells with 1000 ng HIV-1 Tat expression plasmid (+) or 1000 
ng expression vector ptasmid (-). Total cytoplasmic RNA was isolated 
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with the homologous 32p-labeled antisense RNA probe. Lane C repre- 
sents a nontransfected control. The position of migration of the 244-nt 
probe and 123-nt correctly initiated transcripts are indicated. 
vation in vivo by the HIV-1 Tat protein. The analogous 
trinucleotide bulge in TAR-1 RNA is crucial for in vitro 
binding by the HIV-1 Tat protein, as deletion of the TAR- 
1 bulge largely abolishes detection of the single Tat:TAR- 
1 RNA complex in gel shift assays (9, 11-14). Deletion 
of the trinucleotide bulge reduces transactivation in vivo 
by the HIV-1 Tat protein to levels ranging from 0.3 to 
15% that of the wild-type TAR-1 element (12, 3, 29). Our 
previous gel shift experiments with TAR-2 RNAs indi- 
cated that each dinucleotide bulge specifies a distinct 
binding site in vitro for the HIV-2 Tat protein (22). The 
results presented here indicate that each dinucleotide 
bulge also specifies a distinct binding site in vitro for the 
HIV-1 Tat protein. Because the UU:A, TAR-2 RNA was 
bound by the HIV-1 Tat protein with significantly higher 
affinity than the A,,UA TAR-2 RNA (Fig. 2), we conclude 
that the 5' proximal UU bulge specifies a higher affinity 
binding site in vitro for the H IV-1 Tat protein than does the 
3' distal UA bulge. Because gel shift complexes formed 
between the HIV-2 Tat protein and TAR-2 RNAs do not 
resolve as well as the HIV-1 Tat:TAR-2 RNA complexes 
presented here, we could not reach conclusions in our 
previous study about he relative binding affinity in vitro 
of the HIV-2 Tat protein for bulge1 and bulge2 (22). 
When in vivo transactivation of TAR-2 bulge deletions 
was analyzed, we observed differences between activa- 
tion by the HIV-1 Tat protein and our previous results 
with the HIV-2 Tat protein. The HIV-1 Tat protein, unlike 
the HIV-2 Tat protein, is able to efficiently interact in vivo 
with a TAR-2 element containing bulge deletions. The 
HIV-1 Tat protein activated the double bulge deletion to 
levels approximately 50% that of the Wtx LTR (Fig. 3), 
while the HIV-2 Tat protein activated the double bulge 
deletion LTR to levels only 5% that of the wt× LTR (22). 
There is a striking discrepancy, therefore, in this study 
between the in vitro binding and in vivo transactivation 
results for the double bulge deletion TAR-2 RNA element 
and the HIV-1 Tat protein. The in vitro binding properties 
of this mutant RNA would predict that it should be acti- 
vated in vivo very poorly by the HIV-1 Tat protein. This is 
clearly not the case, suggesting that in vivo a cellular 
factor may facilitate HIV-1 Tat protein binding to this mu- 
tant RNA, The most likely candidate for this factor is the 
TAR RNA loop binding factor that has been proposed 
from elegant genetic experiments to bind the Tat protein 
prior to Tat binding to TAR RNA (20). We cannot, of 
course, exclude the possibility that the HIV-1 Tat protein 
binds to a nonbulge site in TAR-2 RNA not identified in 
our gel shift assays. Finally, an implication of this study 
is that the HIV-1 Tat protein, but not the HIV-2 Tat protein, 
may be able to activate transcription of cellular mRNAs 
whose nascent transcripts contain no apparent bulge 
binding site. Activation of some cellular genes bythe HIV- 
1 Tat protein may affect HIV-1 infection and contribute to 
particular pathogenic features of HIV-1. 
ACKNOWLEDGM ENTS 
We thank Christine Herrmann and Ronald Javier for critical comments 
on the manuscript. This research was supported by NIH Grant AI- 
25308. 
REFERENCES 
1, WQNG-STAAL, F., //3 "Virology" (B. N. Fields, Ed.), pp. 1529-1544. 
Raven Press, New York, 1990. 
2. JONES, K. A., Ourr. BioL 5, 461-468 (1993). 
3. EMERMAN, M., GUYADER, M., MONTAGMER, L, BALTIMORE, D., and 
MUES/NG, M. A., EMBO .L 6, 3766-3760 (1987). 
4. ARYA, S. K., and GALLO, R. C., Prec. Natl. Acad. ScL USA 85, 9753- 
9757 (1988). 
5. EENRIOK, R., MALIM, M., HAUBER, J., LE, S-Y, MAIZEL, J., and CULLEN, 
B. R., J. ViroL 63, 5006 5012 (1989), 
6. BERKHOUT, B., GATIGNOL, A., SILVER, ]., and JEANG, K-T, Nucleic Acids 
Res. 18, 1839-1846 (1990). 
7.. ELANGOVAN, B., SUBRAMANIAN, T., and CHINNADURAI, G., J. ViroL 66, 
203t-2036 (1992). 
678 SHORT COMMUNICATIONS 
8. CHANG, Y-N., and JEANG, K-T., Nucleic Acids Res. 20, 5465-6472 
(1992). 
9. RHIM, H., and RicE, A. P.,J. ViroL 67, 1110-1121 (1993). 
10. GAIT, M. J., and KARN, J., Trends Biochem. ScL 18, 255-259 (1993). 
11. CORDINGLEY, M. G., LAFEMINA, R. L., CALLAHAN, P. L., CONDRA, J. H., 
SARDANA, V. V., GRAHAM, D. J., NGUYEN, T. M., LEGROw, K., GOTL[B, 
L, SCHLABACH, A. J., and COLONNO, R. J., Proc. Natl. Acad. ScL 
USA 87, 8985-8989 (1990). 
12. DINGWALL, C., ERNBERG, I., GAIT, M. J., GREEN, S. M., HEAPHY, S., 
KARN, J., LOWE, A. D., SINGH, M., and SKINNER, M. A., EMBO .L 9, 
145-4153 (1990). 
73. BoY, S., DELLING, U., CHEN, c.-m., ROSEN, C. A., and SONENBERG, N., 
Genes Dev. 4, 1365 1373 (1990). 
14. CALNAN, B. J., BIANOALANA, S., HUDSON, D., and ERANKEL, A. D., Genes 
Dev. 5, 201 210 (1991). 
15. CHURCHER, M. J., LAMONT, C., HAMY, F., DINGWALL, C., GREEN, S. M., 
LOWE, A. D., BUTLER, P. J. G., GAIT, M. J., and KARN, J., J. MoL Biol. 
230, 90-110 (1993). 
16. Luo, Y., MADORE, S. J., PARLSOW, T. G., CULLEN, a. R., and PETERLIN, 
B. M., Z Virel. 67, 5617-5622 (1993). 
17. SOUTHGATE, C., ZARP, M. L., and GREEN, M. R., Nature 345, 640- 
642 (1990). 
18. SELBY, M. J., and PETERLIN, B. M., Cell 62, 769-776 (1990). 
19. CARROLL, R., PETERLIN, B. M., and DERSE, U., J. ViroL 66, 2000-2007 
(1992). 
20. MADORE, S. J., and CULLEN, B. R., Z ViroL 67, 3703-3711 (1993). 
21. SELBY, M. J., BAIN, E. S., LucIw, P. A., and PETERLIN, B. M., Genes 
Dev. 3, 547-558 (1989). 
22. RHIM, H. and RICE, A. P., Virology 202, 202-211 (1994). 
23. DERY, C. V., HERRMANN, C. H., and MATHEWS, M. B., Oncogene 2, 
16-23 (1987). 
24. OULLEN, B. m., Cell 46, 973-982 (1986). 
25. RHIM, H., CHAN, F., ECHETEBU, C. O., and RICE, A. P., Protein Express. 
Purif: 4, 24-31 (1993). 
26. SAMBROOK, J., FRITSOH, E. F., and MANIATIS, T., "Molecular Cloning." 
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New 
York, 1989. 
2Z MARR/OH, D., GAROIA, J., MITSUYASU, R., and GAYNOR, R., EMBO Z 9, 
4417-4423 (1990). 
28. TAYLOR, J. P., POMERANTZ, R., BAGASRA, O., CHOWDHURY, M., RAPPA- 
PORT, J., KHALILI K., and AMINI, S., EMBOJ. t 1, 3395 3403 (1992). 
29. BERKHOUT, B., and JEANG, K.-T. J. ViroL 63, 5501-5504 (1989). 
